By Fineline Cube 
Skyhawk Therapeutics, Inc. announced on August 18, 2025, a strategic research collaboration with Merck KGaA (ETR: MRK). The partnership will focus on discovering novel RNA-targeting small molecules for specific neurological indications.
Collaboration Details
Under the agreement, Skyhawk will utilize its proprietary SkySTAR (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) platform to identify small molecule candidates targeting specific RNA targets designated by Merck. The collaboration aims to expand the potential of RNA modulation in diseases where traditional approaches have proven challenging. This partnership leverages Skyhawk’s industry-leading capabilities in RNA splicing modulation and Merck’s expertise in drug development and commercialization.
Financial Terms
Skyhawk will lead the discovery and preclinical development efforts. Upon option exercise, Merck will assume responsibility for further development and commercialization. The total deal value exceeds $2 billion. Skyhawk is also eligible for milestone payments and tiered royalties on commercial sales.-Fineline Info & Tech